Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...
At Multiple Sclerosis News Today, stories about the keto diet, myelin repair, and vitamin D topped this year's most-read list ...
A single dose of Immutep’s MS therapy, IMP761, was well tolerated and reduced T-cell activity for up to 23 days in healthy ...
WEDNESDAY, Dec. 17, 2025 (HealthDay News) — An over-the-counter supplement called lipoic acid might help slow the loss of gray matter in the brains of people with progressive multiple sclerosis (MS), ...
Patients included in a new study were grouped by initiation of high-efficacy or moderate-efficacy disease-modifying therapy (DMT). The most common reasons for DMT de-escalation were positivity for JC ...
"The observed differential effects of high-efficacy disease-modifying agents across sexes underscore the importance of sex-specific considerations in making treatment decisions to personalize care in ...
The Breakthrough Prize has announced its 2025 Laureates in Life Sciences, Fundamental Physics, and Mathematics. Among them are Professors Alberto Ascherio from Harvard University and Stephen Hauser ...
He revealed more recently he had bio-cellular therapy treatment on his spine Kevin Winter/Getty Jack Osbourne is opening up about his Multiple Sclerosis (MS) diagnosis. The 38-year-old media ...
PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback